Topoisomerase II and leukemia.

Area of Science:

• Molecular Biology
• Genetics
• Pharmacology

Background:

• Type II topoisomerases regulate DNA topology, essential for cellular processes.
• These enzymes are targeted by widely used anticancer drugs (topoisomerase II poisons).
• Topoisomerase II poisons induce DNA breaks by stabilizing enzyme-cleaved DNA complexes.

Purpose of the Study:

• To elucidate the mechanism of type II topoisomerase and topoisomerase II poison action.
• To investigate how topoisomerase II poisons induce chromosomal breaks and lead to leukemia.
• To explore strategies for dissociating the anti-cancer effects of these drugs from their leukemogenic potential.

Main Methods:

• Review of existing literature on type II topoisomerases, their inhibitors, and associated leukemogenesis.
• Analysis of drug mechanisms and their interaction with DNA and topoisomerase II.
• Examination of chromosomal rearrangements linked to specific topoisomerase II poisons and leukemia types.

Main Results:

• Topoisomerase II poisons, including etoposide, doxorubicin, and mitoxantrone, are effective anticancer agents but carry risks.
• Drug-induced DNA breaks are implicated in specific leukemias, such as acute myeloid leukemia with 11q23 rearrangements (etoposide, doxorubicin) and acute promyelocytic leukemia with t(15;17) (mitoxantrone, epirubicin).
• Naturally occurring topoisomerase II-active compounds in diet may also contribute to infant leukemias.

Conclusions:

• Understanding the dual action of topoisomerase II poisons is critical for cancer therapy.
• Further research is needed to develop safer topoisomerase II-targeting anticancer drugs.
• Strategies to mitigate the leukemogenic potential of these essential drugs are a key area for future investigation.